SU833258A1 - Method of prophylaxis and treatment of disentery - Google Patents
Method of prophylaxis and treatment of disentery Download PDFInfo
- Publication number
- SU833258A1 SU833258A1 SU792859686A SU2859686A SU833258A1 SU 833258 A1 SU833258 A1 SU 833258A1 SU 792859686 A SU792859686 A SU 792859686A SU 2859686 A SU2859686 A SU 2859686A SU 833258 A1 SU833258 A1 SU 833258A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- live
- billion
- vaccine
- prophylaxis
- days
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
(54) СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ДИЗЕНТЕРИИ(54) METHOD FOR PREVENTION AND TREATMENT OF DYSENTERIA
II
Изобретение относитс к медицине и касаетс профилактики и лечени инфекционных заболеваний, а именно дизентерии.This invention relates to medicine and concerns the prevention and treatment of infectious diseases, namely dysentery.
Известен способ профилактики и лечени дизентерии путем перорального введени живой дизентерийной вакцины из стрептомицинзависимых штаммов (1J.There is a known method for the prevention and treatment of dysentery by oral administration of live dysentery vaccine from streptomycin-dependent strains (1J.
Однако известный способ недостаточно эффективен, так как не происходит иарастание уровн антител, в особенности JgA класса, сроки выделени возбудител длительны , возможны обострени воспалительной реакции и слизистой кишечника.However, the known method is not sufficiently effective, since there is no growth of the antibody level, especially of the JgA class, the timing of the release of the pathogen is long, and exacerbations of the inflammatory response and the intestinal mucosa are possible.
Цель изобретени - повышение эффективности способа за счет нарастани уровн антител, в особенности JgA класса, сокращение сроков выделени возбудител , сроков репарации слизистой и снижение побочных реакций.The purpose of the invention is to increase the efficiency of the method by increasing the level of antibodies, especially the JgA class, reducing the time required for the release of the pathogen, the time needed for repairing the mucous membrane, and reducing side reactions.
Эта цель достигаетс тем, что перорально ввод т живую дизентерийную вакцину из спонтанных мутантов Флекснера 2а516м и Зонне 65 по следующей схеме: дл иммунопрофилактики взрослых трехкратно с интервалом З-7 дней в дозах 25, 25-50 и 50-75 млрд живых микробных клеток; дл иммунопрофилактики детей в возрасте 7-14This goal is achieved by orally administering live dysenteric vaccine from spontaneous mutants of Flexner 2a516m and Sonne 65 according to the following scheme: for immunoprophylaxis of adults three times with an interval of 3-7 days in doses of 25, 25-50 and 50-75 billion live microbial cells; for immunization in children aged 7-14
лет-двух-или трехкратно с интервалом 5- 12 дней в дозе 6-25 млрд живых микробных «леток; дл иммунотерапии взрослых - одно-двукратно с интервалом дней в дозах 25-50 млрд живых микробных клеток .years — two or three times with an interval of 5–12 days at a dose of 6–25 billion live microbial cells; for adult immunotherapy, once or twice a day at doses of 25–50 billion live microbial cells.
Живую дизентерийную вакцину готов т следующим образом.A live dysentery vaccine is prepared as follows.
Восемнадцатичасовую агаровую культуру вакционного штамма смывают охлажденным раствором наполнител (10% сахорозыEighteen hour agar culture of the vaccine strain is washed off with a cooled filler solution (10% sucrose
и желатины), вз том в количестве 10-12 мл на один матрац, содержащем 200мл м со-пептонного агара, и лиофильно высу:шивают в ампулах или готов т в виде дра;же . На всех этапах приготовлени вакциныand gelatins), taken in an amount of 10-12 ml per mattress containing 200 ml of m-peptone agar, and lyophilized: sewed in ampoules or prepared in the form of core; At all stages of vaccine preparation
- соблюдаютс правила стерильности и охлаждени микробной массы.- the rules of sterility and cooling of the microbial mass are observed.
Приготовленна таким образом жива дизентерийна вакцина не должна содержать посторонней микробной флоры (в том 1исле canpoJfcJTHoA гемолитической, грибков,A dysentery vaccine prepared in this way should not contain extraneous microbial flora (including canpoJfcJTHoA hemolytic, fungi,
В споровых микрооргаиизмов и др.) Вакцина должна иметь не менее 15% живых микробных клеток вакционного щтамма, который должен находитьс в S-форме. Количество ; R-колонин в попул ции щтамма Зонне QSIn spore microorganisms, etc.) The vaccine must have at least 15% of the living microbial cells of the vaccine system, which must be in S-form. Amount ; R-colonies in the population of Zonam Zonne QS
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU792859686A SU833258A1 (en) | 1979-12-28 | 1979-12-28 | Method of prophylaxis and treatment of disentery |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU792859686A SU833258A1 (en) | 1979-12-28 | 1979-12-28 | Method of prophylaxis and treatment of disentery |
Publications (1)
Publication Number | Publication Date |
---|---|
SU833258A1 true SU833258A1 (en) | 1981-05-30 |
Family
ID=20867956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU792859686A SU833258A1 (en) | 1979-12-28 | 1979-12-28 | Method of prophylaxis and treatment of disentery |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU833258A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2651752C1 (en) * | 2017-07-31 | 2018-04-23 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации | Method for treating erased forms of dysentery |
-
1979
- 1979-12-28 SU SU792859686A patent/SU833258A1/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2651752C1 (en) * | 2017-07-31 | 2018-04-23 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации | Method for treating erased forms of dysentery |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sack et al. | Progressive changes of Vibrio serotypes in germ-free mice infected with Vibrio cholerae | |
Baumgartner et al. | Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid | |
Michalek et al. | Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity | |
US4341763A (en) | Methods of vaccinating humans against rotavirus infection | |
Kodama et al. | Studies of live attenuated Japanese encephalitis vaccine in swine | |
US4117112A (en) | Vaccine for prevention of feline leukemia | |
US3944469A (en) | Feline calicivirus vaccine and production thereof | |
US3937812A (en) | Feline calicivirus vaccine and production thereof | |
Yoshie | On the isolation of influenza virus from mid-ear discharge of influenza otitis media | |
EP0484438B1 (en) | Biological preparation and its use | |
US4731245A (en) | Vaccine, antigen and antibody for treating microorganisms of the MCLS-type streptococcus sanguis | |
Ayuya et al. | The immunological response of the rat to infection with Taenia taeniaeformis: VII. Immunization by oral and parenteral administration of antigens | |
SU833258A1 (en) | Method of prophylaxis and treatment of disentery | |
Bratthall et al. | Antigenic variation of Streptococcus mutans colonizing gnotobiotic rats | |
Mark et al. | The role of aluminium for adverse reactions and immunogenicity of diphtheria‐tetanus booster vaccine | |
US5925361A (en) | Ornithobacterium rhinotracheale vaccines | |
US4322404A (en) | Process for the production of new mutants of herpes simplex virus type 1 and type 2 | |
Suzuki et al. | Inhibition by Lipopolysaccharide (Endotoxin) of Antibody Response of Rabbit to Common Antigen of Enterobacteriaceae. | |
Woodward | Rickettsial vaccines with emphasis on epidemic typhus-initial report of an old vaccine trial | |
EP0048422A2 (en) | Pili of pseudomonas aeruginosa and utilization of same as vaccines against infectionary p.aeruginosa | |
US4340588A (en) | Brucellosis vaccine for cattle containing mycolate esters of trehalose | |
US4215107A (en) | Parainfluenza virus vaccine and its preparation | |
US4770875A (en) | Process for preparation of improved mutant strain of Bordetella bronchiseptica useful for live attenuated vaccine for protection of B. bronchiseptica infection and live attenuated AR vaccine produced therefrom | |
Pannell et al. | Studies on the Pathogenesis and Immunity of Tularemia: I. The Demonstration of a Protective Antibody in Mouse Serum | |
Zhdanov | 27. LARGE-SCALE PRACTICAL TRIALS AND USE OF LIVE POLIOVIRUS VACCINE IN THE USSR |